BWAY vs. VAPO, LNSR, ICU, NMRD, NMTC, AFIB, PAVM, TNON, SSKN, and VERO
Should you be buying BrainsWay stock or one of its competitors? The main competitors of BrainsWay include Vapotherm (VAPO), LENSAR (LNSR), SeaStar Medical (ICU), Nemaura Medical (NMRD), NeuroOne Medical Technologies (NMTC), Acutus Medical (AFIB), PAVmed (PAVM), Tenon Medical (TNON), STRATA Skin Sciences (SSKN), and Venus Concept (VERO). These companies are all part of the "surgical & medical instruments" industry.
BrainsWay vs.
BrainsWay (NASDAQ:BWAY) and Vapotherm (NYSE:VAPO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations, community ranking, media sentiment and institutional ownership.
In the previous week, BrainsWay had 8 more articles in the media than Vapotherm. MarketBeat recorded 9 mentions for BrainsWay and 1 mentions for Vapotherm. Vapotherm's average media sentiment score of 0.23 beat BrainsWay's score of 0.06 indicating that Vapotherm is being referred to more favorably in the news media.
BrainsWay presently has a consensus target price of $7.25, suggesting a potential upside of 340.73%. Vapotherm has a consensus target price of $4.75, suggesting a potential upside of 703.04%. Given Vapotherm's higher possible upside, analysts plainly believe Vapotherm is more favorable than BrainsWay.
BrainsWay has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500. Comparatively, Vapotherm has a beta of -1.08, meaning that its share price is 208% less volatile than the S&P 500.
BrainsWay has a net margin of -49.12% compared to Vapotherm's net margin of -169.55%. BrainsWay's return on equity of -26.22% beat Vapotherm's return on equity.
BrainsWay has higher earnings, but lower revenue than Vapotherm. BrainsWay is trading at a lower price-to-earnings ratio than Vapotherm, indicating that it is currently the more affordable of the two stocks.
47.9% of BrainsWay shares are owned by institutional investors. Comparatively, 59.0% of Vapotherm shares are owned by institutional investors. 19.0% of BrainsWay shares are owned by company insiders. Comparatively, 10.6% of Vapotherm shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Vapotherm received 33 more outperform votes than BrainsWay when rated by MarketBeat users. However, 63.95% of users gave BrainsWay an outperform vote while only 54.32% of users gave Vapotherm an outperform vote.
Summary
BrainsWay beats Vapotherm on 12 of the 18 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding BWAY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BrainsWay Competitors List
